Skip to main content

Mission Investments

Home>Key initiatives>Australian Brain Cancer Mission>Mission Investments>
A A

The Australian Government and Mission Funding Partners have awarded a total of $38.71 million to Medical Research Future Fund (MRFF) initiatives under the Mission:
 
  • $5.002 million - Zero Childhood Cancer Initiative - University of New South Wales
  • $2.50 million - Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) - Monash University
  • $7.16 million – Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) - Monash University (co-funded with Financial Markets Foundation for Children, the Robert Connor Dawes Foundation and Carrie’s Beanies 4 Brain Cancer)
  • $2.50 million - Cooperative Trials Group for Neuro-Oncology (COGNO) - University of Sydney
  • $0.251 million - COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs - Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)
  • $0.453 million - SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, molecularly-targeted CHK1/2i Therapy, in combination with cyclophosphamide or gemcitabine for children and adolescents with refractory or recurrent medulloblastoma brain tumours - Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)
  • $2.422 million - MAGMA: Multi-Arm GlioblastoMa Australasia Trial - University of Sydney (co-funded with Carrie’s Beanies 4 Brain Cancer and the Mark Hughes Foundation)
  • $1.391 million - PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma - University of Sydney
  • $1.246 million - FET-PET in Glioma (FIG Study) - La Trobe University
  • $0.503 million – LUMOS: Low & intermediate grade glioma umbrella study of molecular guided therapies - University of Sydney
  • $0.574 million - Role of the NKp44-PDGF-DD axis in glioblastoma - University of Melbourne
  • $0.48 million – PARC: A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) relapsed/refractory cancers of children and young adults - Monash University
  • $0.384 million - Targeted invadapodia to treat glioblastomas - University of Melbourne
  • $4.973 million – BRAIN: Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs - University of Sydney
  • $1.942 million - A new nurse-led intervention to re-engage childhood brain cancer survivors - University of New South Wales
  • $2.615 million - Responding to need: technology-enhanced brain cancer survivorship - University of Melbourne
  • $0.88 million - MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients - Monash University
  • $0.323 million - CONNECT 1903: A pilot and surgical study of larotrectinib for disease control in children with newly-diagnosed high-grade glioma with NTRK fusion - Monash University
  • $1.129 million - LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents - University of New South Wales
  • $1.983 million – LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS - University of Sydney
In addition, Mission Funding Partners have invested a further $52.19 million under the Mission, including both co-investments with the MRFF (as detailed above) and independently managed initiatives.